Vilazodone
Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth.
| Clinical data | |
|---|---|
| Pronunciation | /vɪˈlæzədoʊn/ vi-LAZ-ə-dohn |
| Trade names | Viibryd |
| Other names | EMD-68843; SB-659746A |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611020 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Serotonin modulator |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 72% (oral, with food) |
| Metabolism | Liver via CYP3A4 |
| Elimination half-life | 25 hours |
| Excretion | Faecal and renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| PDB ligand | |
| Chemical and physical data | |
| Formula | C26H27N5O2 |
| Molar mass | 441.535 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Common side effects include nausea, diarrhea, and trouble sleeping. Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, mania, pancreatitis, and SIADH. Vilazodone may cause less emotional blunting than typical SSRIs and SNRIs. A withdrawal syndrome may occur if the dose is rapidly decreased. Use during pregnancy and breastfeeding is not generally recommended. It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT1A receptor.
Vilazodone was approved for medical use in the United States in 2011 and in Canada in 2018. In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics. Generic versions have been approved by the U.S. Food and Drug Administration (FDA).